Cross-linkable Nitrosamines with a Chloroalkyl Group as Candidates for Anticancer Lead Compounds

Genes and Environment

Volumn 29, Issue 1, 2007, Pages 1-10

  Ishikawa, Satoko ^a   Mochizuki, Masataka ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56549123426     PISSN: 18807046     EISSN: 18807062     Source Type: Journal    
DOI: 10.3123/jemsge.29.1     Document Type: Article

References (51)

1. Newell D, Gescher A, Harland S, Ross D, Rutty C. N-methyl antitumour agents. Cancer Chemother Pharmacol. 1987; 19: 91-102.
2. Gnewuch CT, Sosnovsky G. A critical appraisal of the evolution of N-nitrosoureas as anticancer drugs. Chem Rev. 1997; 97: 829-1013.
3. Hecht SS, Morrison JB. A sensitive method for detecting in vivo formation of N-nitrosomorpholine and its application to rats given low doses of morpholine and sodium nitrite. Cancer Res. 1984; 44: 2873-7.
4. Lijinsky W. Induction of tumours in rats by feeding nitrosatable amines together with sodium nitrite. Fd Chem Toxicol. 1984; 22: 715-20.
5. Preussmann R, Eisenbrand G. Chemical Carcinogens, 2nd ed. Searle CE, editor. American Chemical Society, Washington, DC, 1984.
6. Marletta MA. Mammalian synthesis of nitrite, nitrate, nitric oxide, and N-nitrosating agents. Chem Res Toxicol. 1988; 1: 249-57.
7. Miwa M, Stuehr DJ, Marletta MA, Wishnok JS, Tannen-baum SR. Nitrosation of amines by stimulated macro-phages. Carcinogenesis. 1987; 8: 955-8.
8. Preussmann R, Stewart BW. Chemical Carcinogens, 2nd ed. Searle CE, editor. American Chemical Society, Washington, DC, 1984.
9. Digenis GA, Issidorides CH. Some biochemical aspects of N-nitroso compounds. Bioorg Chem. 1979; 8: 97-137.
10. Mochizuki M, Suzuki E, Anjo T, Wakabayashi Y, Okada M. Mutagenic and DNA-damaging effects of N-alkyl-N-(a-acetoxyalkyl)nitrosamines, models for metabolically activated N,N-dialkylnitrosamines. Gann. 1979; 70: 663-70.
11. Mochizuki M, Anjo T, Okada M. Syntheses of N-(m-acetoxyalkyl and w-carbomethoxyalkyl)-N-(a-acetoxy-alkyl)nitrosamines, model compounds for possible metabolically activated N,N-dialkylnitrosamines. Chem Pharm Bull. 1978; 26: 3914-9.
12. Mochizuki M, Ikarashi A, Suzuki A, Sekiguchi N, Anjo T, Okada M. The Relevance of N-Nitroso Compounds to Human Cancer (lARC Scientific Publications No. 84). Bartsch H, ONeill I, Shulte-Hermann R, editors. International Agency for Research on Cancer, Lyon, 1987.
13. Mochizuki M, Anjo T, Sekiguchi N, Ikarashi A, Wakabayashi Y, Okada M. Solvolysis of N-nitroso-N-(1-acetoxyalkyl)alkylamines in phosphate buffer: Characterization and mutagenicity of N-nitroso-N-(1-phosphonooxyalkyl)alkylamines. Chem Pharm Bull. 1986; 34: 3956-59.
14. Gold B, Linder WB. a-Hydroxynitrosamines: Transportable metabolites of dialkylnitrosamines. J Am Chem Soc. 1979; 101: 6772-3.
15. Appel KE, Frank N, Wiessler M. Metabolism of nitrosoa-cetoxymethylmethylamine in liver microsomes. Biochem Pharmacol. 1981; 30: 2767-72.
16. Roller PP, Shimp DR, Keefer LK. Synthesis and solvoly-sis of methyl(acetoxymethyl)nitrosamine. Solution chemistry of the presumed carcinogenic metabolite of dimethylnitrosamine. Tetrahedron Lett. 1975; 2065-8.
17. Wiessler M. Nitrosamines. II. Synthesis of a-functional-ized dimethylnitrosamines. Tetrahedron Lett. 1975; 2575-8.
18. Mochizuki M, Anjo T, Okada M. Syntheses of N-alkyl-N-(α-acetoxyalkyl)nitrosamines, model compounds for metabolically activated N,N-dialkylnitrosamines. Chem Pharm Bull. 1978; 26: 3905-8.
19. Saavedra JE. Oxidative decarboxylation of nitrosoamino acids: a synthetic approach to cyclic a-acetoxynitros-amines. Tetrahedron Lett. 1978; 1923-6.
20. Mochizuki M, Suzuki E, Anjo T, Wakabayashi Y, Okada M. Mutagenic and DNA-damaging effects of N-alkyl-N-(α-acetoxyalkyl)nitrosamines, models for metabolically activated N,N-dialkylnitrosamines. Gann. 1979; 70: 663-70.
21. Huang GF, Mochizuki M, Anjo T, Okada M. Mutagenicity of N-alkyl-N-(α-acetoxyalkyl)nitrosamines in V79 Chinese hamster cells in relation to alkylating activity. Gann. 1981; 72: 531-8.
22. Mochizuki M, Anjo T, Okada M. Isolation and characterization of N-alkyl-N-(hydroxymethyl)nitrosamines from N-alkyl-N-(hydroperoxymethyl)nitrosamines by deoxygenation. Tetrahedron Lett. 1980; 21: 3693-6.
23. Mochizuki M, Anjo T, Takeda K, Suzuki E, Sekiguchi N, Huang GF, Okada M. N-Nitroso Compounds: Occurrence and Biological Effects (lARC Scientific Publications No. 41). Bartsch H, ONeill IK, Castegnaro M, Okada M, editors. International Agency for Research on Cancer, Lyon, 1982.
24. Mochizuki M, Osabe M, Anjo T, Suzuki E, Okada M. Mutagenicity of a-hydroxy N-nitrosamines in V-79 Chinese hamster cells. J Cancer Res Clin Oncol. 1984; 108: 290-5.
25. Ukawa-Ishikawa S, Sawada A, Kasuya K, Mochizuki M. Mutagenicity of isomeric alkanediazotates, precursors for ultimate alkylating species of carcinogenic N-nitroso compounds. Mutation Res. 1998; 412: 99-107.
26. Ukawa-Ishikawa S, Seki M, Mochizuki M. Mutagenicity of potassium alkanediazotates in Chinese hamster V79 cells and their alkylating activity. Biol Pharm Bull. 1999; 22: 577-81.
27. Blackburn GM. Nucleic Acids in Chemistry and Biology, Second Edition. Blackburn GM, Gait MJ, editors. Oxford University Press, Oxford, 1996.
28. Lemoine A, Lucas C, Ings RM. Metabolism of the chlo-roethylnitrosoureas. Xenobiotica. 1991; 21: 775-91.
29. Brakenhoff JPG, Commandeur JNM, Wormhoudt LW, Groot EJ, Vermeulen NPE. Molecular mechanisms of toxic effects of fotemustine in rat hepatocytes and subcel-lular rat liver fractions. Carcinogenesis. 1996; 17: 715-24.
30. Lown JW, Koganty RR, Bhat UG, Sapse A-M, Allen EB. Mechanism of interstrand cross-linking of DNA by anticancer 2-haloethylnitrosoureas. Drugs Exptl Clin Res. 1986; 12: 463-73.
31. Pieper RO, Noftz SL, Erickson LC. In vitro transcription termination by N,N-bis(2-chloroethyl)nitrosourea-induced DNA lesions. Mol Pharmacol. 1995; 47: 290-5.
32. Reynolds RC, Tiwari A, Harwell JE, Gordon DG, Garrett BD, Gilbert KS, Schmid SM, Waud WR, Struck RF. Synthesis and evaluation of several new (2-chlo-roethyl)nitrosocarbamates as potential anticancer agents. J Med Chem. 2000; 43: 1484-8.
33. Okada M, Mochizuki M. Nitrosamine derivative. Tokyo Biochemistry Research Committee, Japan Patent, 55102548 (1980).
34. Ishikawa S, Saitoh N, Mochizuki M. Synthesis and properties of novel bifunctional nitrosamines with m-chloroalkyl groups. Chem Pharm Bull. 2000; 48: 1500-3.
35. Ames BN, McCann J, Yamasaki E. Handbook of Mutagenicity Test Procedures. Kilbey BJ, Legator M, Nichols W, Ramel C, editors. Elsevier North-Holland Biomedical Press, Amsterdam, 1977.
36. Hartley JA, Berardini MD, Souhami RL. An agarose gel method for the determination of DNA interstrand cross-linking applicable to the measurement of the rate of total and “second-arm” crosslink reactions. Anal Biochem. 1991; 193: 131-4.
37. Ishikawa S, Mochizuki M. Mutagenicity and cross-linking activity of chloroalkylnitrosamines, possible new an-titumor lead compounds. Mutagenesis. 2003; 18: 331-5.
38. Hildrum KI, Scanlan RA, Libbey LM. Formation of volatile, hydroxylated, and chlorinated N-nitrosamines during the nitrosation of spermidine 3-hydrochloride. J Agric Food Chem. 1977; 25: 252-7.
39. Druckrey H, Preussmann R, Ivankovic S, Schnaehl D. Organotropic carcinogenic effects of 65 various N-nitroso-compounds on BD rats. Z Krebsforsch. 1967; 69: 103-201.
40. Yamada M, Matsui K, Sofuni T, Nohmi T. New tester strains of Salmonella typhimurium lacking O6-methyl-guanine DNA methyltransferases and highly sensitive to mutagenic alkylating agents. Mutation Res. 1997; 381: 15-24.
41. Murray ML. Substrate-specificity of uvr excision repair. Environ Mutagen. 1979; 1: 347-52.
42. Eckhardt S. Recent progress in the development of anticancer agents. Curr Med Chem Anti-Cancer Agents. 2002; 2: 419-39.
43. Brafia MF, Cacho M, Gradillas A, de Pascual-Teresa B, Ramos A. Intercalators as anticancer drugs. Curr Phar-maceut Des. 2001; 7: 1745-80.
44. Fan J-Y, Valu KK, Woodgate PD, Baguley BC, Denny WA. Aniline mustard analogs of the DNA-intercalating agent amsacrine: DNA interaction and biological activity. J Am Chem Soc. 2003; 125: 9629-37.
45. Baraldi PG, Romagnoli R, Guadix AE, Pineda de las Infantas MJ, Gallo MA, Espinosa A, Martinez A, Bingham JP, Hartley JA, Design, synthesis, and biological activity of hybrid compounds between ramustine and DNA minor groove binder distamycin A. J Med Chem. 2002; 45: 3630-8.
46. Denny WA. DNA minor groove alkylating agents. Curr Med Chem. 2001; 533-44.
47. Wang C, Delcros J-G, Biggerstaff J, Pharnstiel O. Synthesis and biological evaluation of N1-(anthracen-9-ylmethyl)triamines as molecular recognition elements for the polyamine transporter. J Med Chem. 2003; 46: 2663-71.
48. Pors K, Paniwnyk Z, Teesdale-Spittle P, Plumb JA, Willmore E, Austin CA, Patterson LH. Alchemix: A novel alkylating anthraquinone with potent activity against anthracycline-and cisplatin-resistant ovarian cancer. Mol Cancer Therapeutic. 2003; 2: 607-10.
49. Ishikawa S, Tajima M, Mochizuki M. Synthesis and properties of bifunctional chloroalkyl nitrosamines with an intercalating moiety. Bioorg Med Chem. 2004; 12: 3791-6.
50. Baguley BC, Denny WA, Atwell GJ, Cain BF. Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacri-dines substituted in the anilino ring. J Med Chem. 1981; 24: 170-7.
51. Sun D, Hansen M, Hurley L. Molecular basis for the DNA sequence specificity of the pluramycins. A novel mechanism involving groove interactions transmitted through the helix via intercalation to achieve sequence selectivity at the covalent bonding step. J Am Chem Soc. 1995; 117: 2430-40.